Vivos Therapeutics Stock In The News

VVOS Stock  USD 5.42  0.19  3.39%   
Our overall analysis of Vivos Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Vivos Therapeutics. The specific impact of Vivos Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Vivos Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher. Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Vivos Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Vivos Therapeutics Backtesting and Vivos Therapeutics Hype Analysis.
For more information on how to buy Vivos Stock please use our How to Invest in Vivos Therapeutics guide.

Vivos Therapeutics Today Top News and Investor Outlook

Investing News at Macroaxis
Vivos sleep apnea device gains Medicare coverage approval
https://www.investing.com/news/company-news/vivos-sleep-apnea-device-gains-medicare-coverage-approval-93CH-4119371
 Bullish
nasdaq News
VOR Skyrockets On Ex-China Rights To Autoimmune Drug, ADIL To Face FDA On Jul.29, PSTV Jumps 14%
https://www.nasdaq.com/articles/vor-skyrockets-ex-china-rights-autoimmune-drug-adil-face-fda-jul29-pstv-jumps-14
 Neutral
Macroaxis News: globenewswire.com
Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada
https://www.globenewswire.com/news-release/2025/06/11/3097541/0/en/Vivos-Therapeutics-Completes-Acquisition-of-The-Sleep-Center-of-Nevada.html
 Bullish
Macroaxis News: globenewswire.com
Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update
https://www.globenewswire.com/news-release/2025/05/15/3082690/0/en/Vivos-Therapeutics-Reports-First-Quarter-2025-Financial-Results-and-Provides-Operational-Update.html
 Neutral
Macroaxis News: globenewswire.com
Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call
https://www.globenewswire.com/news-release/2025/05/14/3081223/0/en/Vivos-Therapeutics-Schedules-Release-of-First-Quarter-2025-Financial-Results-and-Conference-Call.html
 Neutral
Macroaxis News: globenewswire.com
Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update
https://www.globenewswire.com/news-release/2025/03/31/3052795/0/en/Vivos-Therapeutics-Reports-Full-Year-2024-Financial-Results-and-Provides-Operational-Update.html
 Bullish
Macroaxis News: globenewswire.com
Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call
https://www.globenewswire.com/news-release/2025/03/28/3051356/0/en/Vivos-Therapeutics-Schedules-Release-of-Full-Year-2024-Financial-Results-and-Conference-Call.html
 Neutral
Macroaxis News: globenewswire.com
Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea
https://www.globenewswire.com/news-release/2023/11/29/2787639/0/en/Vivos-Therapeutics-Receives-First-Ever-FDA-510-k-Clearance-for-Oral-Device-Treatment-of-Severe-Obstructive-Sleep-Apnea.html
 Neutral
Macroaxis News: globenewswire.com
Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update
https://www.globenewswire.com/news-release/2023/11/14/2780511/0/en/Vivos-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Operational-Update.html
 Bullish
Macroaxis News: globenewswire.com
Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call
https://www.globenewswire.com/news-release/2023/11/09/2777907/0/en/Vivos-Therapeutics-Schedules-Release-of-Third-Quarter-2023-Financial-Results-and-Conference-Call.html
 Neutral

Vivos Therapeutics Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Vivos and other traded companies coverage with news coverage. We help investors stay connected with Vivos headlines for the 25th of July to make an informed investment decision based on correlating the impacts of news items on Vivos Stock performance. Please note that trading solely based on the Vivos Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Vivos Therapeutics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Vivos Therapeutics investors visualize upcoming and past events in order to time the market based on Vivos Therapeutics noise-free hype analysis.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Vivos Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Vivos Therapeutics' short interest history, or implied volatility extrapolated from Vivos Therapeutics options trading.

Additional Tools for Vivos Stock Analysis

When running Vivos Therapeutics' price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.